Yantai Zhenghai Bio-Tech Co. Ltd. Class A

Yantai Zhenghai Bio-Tech Co. Ltd. Class A

SSZSE:300653
13.45
CNY
-0.16
(-1.18%)
0.35EPS
45.05P/E
2.87BMarket Cap
Apr 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.46
0.59
1.05
1.12
1.13
1.19
1.55
1.64
2.23
2.99
2.3
2.02
2.03
1.78
Basic EPS, GAAP
0.3
0.19
0.35
0.34
0.38
0.48
0.59
0.66
0.94
1.28
1.06
0.75
0.46
0.35
Free Cash Flow per Basic Share
- -
0.15
0.33
0.1
0.34
0.39
0.23
0.09
0.87
0.91
0.82
0.76
0.49
- -
Dividend per Share
0.08
0.01
- -
- -
- -
0.22
0.27
0.33
0.17
0.73
0.6
0.8
0.46
- -
Book Value per Share
0.55
1.2
1.33
1.69
2.68
2.94
3.27
3.59
4.36
4.81
5.27
4.94
4.94
4.93
Tangible Book Value per Share
0.41
1.09
1.26
1.55
2.59
2.7
3.04
3.37
4.15
4.6
5.07
4.76
4.78
4.76
Basic Weighted Avg Shares
53
180
123
135
161
180
181
179
179
145
180
180
179
179
Sales/Revenue/Turnover
77
105
128
151
183
216
280
293
400
433
414
363
364
320
Operating Margin (%)
22.71
31.03
30.58
28.32
34.17
39.25
39.12
41.95
43.62
47.36
46.6
36.98
20.76
17.63
Depreciation Expense
- -
3
3
4
4
5
5
6
18
19
21
23
23
- -
Net Income, GAAP
16
34
42
45
62
86
107
118
169
185
191
135
82
63
Effective Tax Rate (%)
15.03
14.5
15.31
15.24
14.33
13.71
13.48
13.3
12.02
12.57
12.56
11.64
6.49
8.55
Profit Margin (%)
20.38
31.96
33.16
30.19
33.74
39.81
38.38
40.35
42.12
42.8
46.16
37.07
22.63
19.85
Working Capital
7
41
152
168
426
464
411
382
537
604
681
632
648
657
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
29
64
179
228
483
529
588
647
785
865
948
889
889
888
Return on Invested Capital (%)
17.06
44.68
27.6
18.37
16.83
16.82
19.02
18.68
23.5
22.31
20.89
14.59
9.34
7.41
Return on Capital (%)
27.76
58.03
34.97
22.31
16.82
16.78
19.22
19.16
23.54
22.47
21.06
14.66
9.27
7.28
Return on Common Equity (%)
- -
72.42
34.97
22.31
17.34
16.96
19.22
19.16
23.54
22.47
21.06
14.66
9.27
7.28

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
180
180
180
Market Capitalization
3,510
2,585
2,869

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
750
722
735
Cash, Cash Equivalents & STI
651
618
631
Accounts Receivable, Net
59
59
55
Inventories
32
33
39
Total Current Liabilities
89
86
78
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.46%
7%
0.08%
Free Cash Flow
102.68%
173.6%
-35.14%
Net Income, GAAP
10.43%
-2.57%
-38.79%
Sales/Revenue/Turnover
11.97%
5.65%
0.25%
Total Cash Common Dividend
- -
38.87%
-43.25%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
108
93
72
363
2025
97
90
- -
88
364
2026
81
79
71
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.25
0.22
0.05
0.75
2025
0.15
0.11
- -
0.08
0.46
2026
0.08
0.1
0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.46
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kan Song
Full Time Employees
379
Sector
Health technology
Industry
Medical specialties
Address
No. 10 Hengshan Road Yantai SD China 264006
IPO Date
May 16, 2017
Business
Yantai Zhenghai Biotechnology Co., Ltd. (300653.SZ) develops, manufactures, and sells magnetic biomaterials and related medical products for orthopedic and dental applications. The company offers a range of bio-orthopedic implants including artificial bone substitutes such as NanoBone, MBCP+, and hydroxyapatite (HA) products; spinal fusion devices like interbody fusion cages and pedicle screws; dental bone graft materials; and wound dressings incorporating silver ions and other bioactive components. These products cater to hospitals, clinics, and dental practices primarily in China, with expanding operations in Asia and select international markets. Founded in 2005 and headquartered in Yantai, Shandong Province, China, the company operates in the biomedical materials segment of the healthcare industry, focusing on tissue engineering and regenerative medicine solutions for bone repair, spinal surgery, and oral implantation. Zhenghai Biotechnology maintains production facilities in Yantai and collaborates with research institutions to advance bioactive ceramics and resorbable implants. It serves as a key supplier to domestic medical device distributors and has no major subsidiaries or parent entities publicly noted. In recent developments, the company announced a strategic partnership in 2024 with a leading European biomaterials firm to co-develop next-generation resorbable spinal implants for Asian markets. Zhenghai completed a RMB 500 million funding round in early 2025 led by domestic healthcare investors to expand manufacturing capacity for its NanoBone product line. Additionally, it launched its ZenGraft dental regeneration system in mid-2025, targeting the growing oral surgery sector, and reorganized its R&D division to prioritize AI-assisted biomaterial design amid competitive pressures in China's medtech landscape.